Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates

Oncodesign与TiumBio签署纤维化候选药物研发合作协议

2021-10-21 18:00:10 BioSpace

本文共2640个字,阅读需7分钟

Collaboration is based on Oncodesign’s Nanocyclix® technology and TiumBio’s fibrosis-centered R&D expertise Agreement also foresees option for in-licensing global development and commercialization rights for TiumBio DIJON, France & PANGYO, South Korea--(BUSINESS WIRE)-- Regulatory News: Oncodesign (ALONC – FR0011766229), a French biopharmaceutical company specialized in kinase inhibitor research and precision medicine, and TiumBio (KOSDAQ:321550), a company specializing in R&D for rare diseases, have announced the signature of a research collaboration agreement on R&D of potential drug candidates for fibrosis. Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio. Also, TiumBio has secured an exclusive option to in-license global development and commercialization rights of the discovered drug candidates after their evaluation upon reaching predefined success criteria. Financial conditions for this option, which might be lifted over the next year, cannot be disclosed at this stage. Hun-Taek Kim, CEO of TiumBio, stated: “We are delighted to work with Oncodesign to achieve our common goal of developing treatments for rare and incurable diseases. If we combine Oncodesign's kinase inhibitor-based platform technology and our fibrosis-centered R&D experience and expertise in rare diseases, I am confident that we can develop new and innovative drugs in the fibrosis area.” Philippe Genne, CEO and founder of Oncodesign, said: “This new collaboration with TiumBio, an expert company in fibrosis in South-Korea, further expands the global reach of our unique technologies. Following earlier collaborations with international pharmaceutical companies including BMS (Bristol-Myers-Squibb), Ipsen, Sanofi, Servier and UCB, our platform technology Nanocyclix® again is poised to bring solutions in a difficult area. I am thrilled to team up with TiumBio to find solutions for patients suffering from Fibrosis.” Jan Hoflack, CSO of Oncodesign, added: “This agreement is another example where an expert pharma company looking for compounds with unique and hard-to-meet criteria comes to benefit from our Nanocyclix® technology platform, looking for high potency and exquisite selectivity. Upfront testing of the Nanocyclix® diversity set has allowed to identify starting points satisfying TiumBio’s initial criteria and has led to this exciting collaboration.” About Fibrosis Fibrosis occurs in most tissues of the human body, which is a phenomenon of fibrous connective tissue formation. As the disease progresses, the function of the corresponding organ is defected, which can lead to various chronic fatal disease conditions such as pulmonary and liver fibrosis. In addition, fibrosis accounts for about 45% of all cause disease mortality1, and since there are few effective treatments currently available, it is a disease area with a very high unmet medical demand from patients. About TiumBio In 2018, TiumBio licensed out the patent right of ‘NCE401’, a drug candidate which was in preclinical stage for pulmonary fibrosis treatment, to Chiesi Farmaceutici, an Italian pharmaceutical company. Last year, the drug candidate for NASH treatment was selected as a BIG3 government project. In addition, it has a number of new fibrosis pipelines and in development, and is known to conduct R&D to expand indication areas such as liver and renal fibrosis. It is believed that this joint R&D collaboration, signed by TiumBio, which has strengths in fibrosis R&D, can be a catalyst to spur the development of fibrosis treatment. About Oncodesign Oncodesign is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and has been listed on Euronext Growth Market since April 2014. Its mission is the discovery of effective therapies to fight cancer and other diseases without therapeutic solutions. With its unique experience acquired by working with more than 1 000 clients, including the world’s largest pharmaceutical companies, along with its unique technological platform combining Artificial Intelligence, state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging, Oncodesign is able to select new therapeutic targets, design and develop potential preclinical candidates through to clinical phases. Oncodesign has configured its organization to offer innovative services to its customers and to license its proprietary molecules. Applied to kinase inhibitors, which represent a market estimated at over $65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with global pharmaceutical groups. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 233 employees within 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA. www.oncodesign.com Disclaimer This press release contains certain forward - looking statements and estimates concerning the Company’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the Company’s control. Consequently, the actual results, financial condition, performances and/or achievements of the Company or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and the Company undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law. _________________ 1 Nature 587, 555-566 (2020) View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005985/en/ Oncodesign Philippe Genne Chairman and CEO Tel. : +33 (0)380 788 260 investisseurs@oncodesign.com NewCap Investor Relations Mathilde Bohin / Louis-Victor Delouvrier Tel. : +33 (0)144 719 495 oncodesign@newcap.eu NewCap Media Relations Arthur Rouillé Tel. : +33 (0)144 710 015 oncodesign@newcap.eu Source: Oncodesign View this news release online at: http://www.businesswire.com/news/home/20211020005985/en
合作基于Oncodesign的NanCyclix®技术和TiumBio以纤维化为中心的研发专业知识 该协议还预见到TiumBio的全球开发和商业化权利的许可选择 法国第戎和韩国PANGYO--(商业电报)--监管新闻: 专门从事激酶抑制剂研究和精准医疗的法国生物制药公司Oncodesign(ALONC-FR0011766229)和专门从事罕见病研发的公司TiumBio(KOSDAQ:321550),日前宣布就纤维化潜在候选药物研发签署研究协作协议。 根据该协议,Oncodesign将负责Nanocyclix®候选药物的识别、化学合成和优化及其早期分析,而TiumBio将负责候选药物纤维化疗效的高级评估。合作的初始阶段将由TIUMBIO资助。 此外,TiumBio还获得了独家选择权,在达到预定的成功标准后,对所发现的候选药物进行评估,获得全球开发和商业化权利的许可。这一选项的财务条件可能在明年取消,现阶段无法披露。 TiumBio首席执行官Hun-Taek Kim表示:“我们很高兴与Oncodesign合作,以实现我们开发罕见和不治之症治疗方法的共同目标。如果我们结合Oncodesign基于激酶抑制剂的平台技术,以及我们以纤维化为中心的研发经验和罕见疾病方面的专业知识,我有信心我们可以在纤维化领域开发出新的创新药物。“ Oncodesign首席执行官兼创始人菲利普·杰内(Philippe Genne)表示:“与韩国纤维化专家公司TiumBio的新合作进一步扩大了我们独特技术的全球影响力。继之前与包括BMS(百时美施贵宝)、Ipsen、Sanofi、Servier和UCB在内的国际制药公司合作后,我们的平台技术Nanocyclix®再次准备在一个困难的领域带来解决方案。我很高兴与TiumBio合作,为纤维化患者找到解决方案。“ Oncodesign的首席执行官简·霍弗莱克(Jan Hoflack)补充说:“这项协议是另一个例子,一家寻找具有独特和难以满足标准的化合物的专家制药公司受益于我们的NanCyclix®技术平台,寻求高效能和精致的选择性。NanCyclix®多样性集的前期测试允许确定满足Tiumbio最初标准的起点,并导致了这一令人兴奋的合作。“ 关于纤维化 人体大部分组织都发生纤维化,是纤维结缔组织形成的一种现象。随着病情的进展,相应器官的功能出现缺陷,可导致肺、肝纤维化等多种慢性致死性疾病状况。此外,纤维化约占所有导致死亡的疾病的45%,由于目前有效的治疗方法很少,它是一个疾病领域,患者的医疗需求非常高。 关于TiumBio 2018年,TiumBio将处于临床前阶段的肺纤维化治疗候选药物'NCE401'的专利权授权给意大利制药公司Chiesi Farmaceutici。去年,治疗纳什的候选药物被选为BIG3政府项目。此外,它还拥有多条新的纤维化管道和正在开发中,并已知进行研发以拓展肝肾纤维化等适应症领域。相信在纤维化研发方面具有实力的TiumBio签署的此次联合研发合作,能够成为推动纤维化治疗发展的催化剂。 关于肿瘤设计 Oncodesign是一家致力于精准医疗的生物制药公司,由现任CEO兼大股东于1995年创立,2014年4月起在泛欧交易所成长市场上市。它的使命是发现有效的疗法来对抗癌症和其他没有治疗方案的疾病。凭借与包括全球最大制药公司在内的1000多家客户合作所获得的独特经验,以及结合人工智能、最先进的药物化学、药理学、调控生物分析、医学成像的独特技术平台,Oncodesign能够选择新的治疗靶点,设计和开发潜在的临床前候选药物,直至临床阶段。Oncodesign已将其组织配置为向其客户提供创新服务并授权其专有分子。应用于激酶抑制剂,到2027年,激酶抑制剂的市场估计超过650亿美元,占制药业研发支出的近25%,Oncodesign的技术已经能够在肿瘤学和其他领域以及与全球制药集团的合作伙伴关系中靶向几种具有巨大治疗潜力的有前途的分子。Oncodesign位于法国第戎,位于该镇大学和医院中心的中心,位于巴黎-萨克莱集群内。Oncodesign在3个业务部门(BU)拥有233名员工:服务、生物技术、人工智能以及在加拿大和美国的子公司。www.oncodesign.com 免责声明 本新闻稿包含有关公司财务状况、经营业绩、战略、项目和未来业绩及其经营市场的某些前瞻性陈述和估计。这种前瞻性陈述和估计可以用诸如“预期”、“相信”、“可以”、“可能”、“估计”、“预期”、“打算”、“旨在”、“可能”、“可能”、“计划”、“潜在”、“预测”、“目标”、“应该”或这些或类似表达的否定词来识别。它们纳入了所有不是历史事实的主题。前瞻性陈述、预测和估计是基于管理层对风险、不确定性和其他已知和未知因素的当前假设和评估,这些假设和评估在作出时被认为是合理的,但可能被证明是不正确的。事件和结果难以预测,取决于公司无法控制的因素。因此,本公司或本行业的实际业绩、财务状况、表现及/或成就可能与该等陈述、预测及估计所表达或暗示的未来业绩、表现或成就有重大差异。由于该等不确定因素,本处并无就该等前瞻性陈述、预测及估计的正确性或公平性作出陈述。此外,前瞻性陈述、预测和估计仅限于其作出之日,本公司不承担任何义务更新或修改其中任何陈述、预测和估计,无论是由于新信息、未来事件或其他原因,除非法律要求。 _______________ 1自然587,555-566(2020) 在businesswire.com查看源代码版本:https://www.businesswire.com/news/home/20211020005985/en/ 肿瘤设计 菲利普·杰内 董事长兼首席执行官 电话。:+33(0)380 788 260 investisseurs@oncodesign.com 纽卡普 投资者关系 玛蒂尔德·博欣/路易斯-维克多·德鲁维耶电话。:+33(0)144 719 495 @newcap.eu 纽卡普 媒体关系Arthur Rouillé 电话。:+33(0)144 710 015 @newcap.eu 来源:Oncodesign 在网上查看此新闻稿: http://www.businesswire.com/news/home/20211020005985/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文